All In Biotech

Free tool

FAERS Monitor: Sulfamylon

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 016763 or its brand name (Sulfamylon, Mafenide Acetate). Reports on generic versions are filed under their own applications.

Reports

31

Serious

25

81% of reports

Hospitalization

11

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective4
  • pyrexia4
  • sepsis4
  • wound infection3
  • agitation2
  • anxiety2
  • clostridium difficile colitis2
  • dry skin2
  • erythema2
  • fatigue2
  • gait disturbance2
  • hypotension2
  • medication error2
  • multiple organ dysfunction syndrome2
  • nausea2

Reports by year received

View as table
YearReports
20041
20051
20061
20081
20122
20141
20154
20164
20186
20192
20201
20212
20222
20231
20241
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
wound infectionSignal3185.963.4382
clostridium difficile colitis2128.033.5141
multiple organ dysfunction syndrome247.912.551
medication error224.46.425
sepsisSignal424.39.768
agitation218.54.818
dry skin210.22.79
pyrexiaSignal47.83.118
gait disturbance27.11.95
hypotension26.81.85
erythema26.61.75
anxiety24.81.23
drug ineffective42.10.81
fatigue21.70.50
nausea21.70.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.